Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

Abstract EN

Background.

The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods.

In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments.

Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results.

Alogliptin treatment tended to decrease UAlbCR ( 99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198 ).

Based on % change in UAlbCR, patients were divided into two groups, responders ( < - 25 % ) and nonresponders ( ≥ - 25 % ), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr.

When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20 ) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin ( - 14.6 ± 8.6 versus + 22.8 ± 16.8 % , P = 0.033 ).

Conclusion.

Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.